Invention Grant
- Patent Title: Optimizing mifepristone levels for cushing's patients
-
Application No.: US15133791Application Date: 2016-04-20
-
Publication No.: US09943526B2Publication Date: 2018-04-17
- Inventor: Joseph Belanoff , Coleman Gross
- Applicant: Corcept Therapeutics, Inc.
- Applicant Address: US CA Menlo Park
- Assignee: Corcept Therapeutics, Inc.
- Current Assignee: Corcept Therapeutics, Inc.
- Current Assignee Address: US CA Menlo Park
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: A61K31/122
- IPC: A61K31/122 ; A61K31/135 ; A61K31/136 ; A61K31/567 ; G01N33/94

Abstract:
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Public/Granted literature
- US20160310507A1 OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATENTS Public/Granted day:2016-10-27
Information query